Osterheld H K, Musch E, von Unruh G E, Loos U, Rauschecker H, Mühlenbruch B J
Department of Internal Medicine, University of Bonn, Federal Republic of Germany.
Cancer Chemother Pharmacol. 1988;21(2):156-62. doi: 10.1007/BF00257364.
A sensitive high-performance liquid chromatographic assay has been developed for the measurement of the alkylating cytostatic drug melphalan (4-[bis(2-chloroethyl)amino]-L-phenyl-alanine, or L-phenylalanine-mustard, L-PAM) and its two hydrolysis products, monohydroxy melphalan (MOH) and dihydroxy melphalan (DOH). A reversed-phase phenyl column and a mobile phase consisting of acetonitrile/citrate buffer made possible an isocratic separation and quantification. N,N-[bis(2-hydroxy-ethyl)]toluidine has been synthesized as an internal standard structurally related to DOH. A new, accurate "kinetic" calibration procedure enabled us to determine even the concentration of the unstable MOH. The lower limit of quantification was 30 ng/ml for L-PAM and 20 ng/ml for both DOH and MOH with fluorescence detection. The use of this method is illustrated by some pharmacokinetic data in systemic and locoregional melphalan therapy.
已开发出一种灵敏的高效液相色谱分析法,用于测定烷化剂细胞抑制药物美法仑(4-[双(2-氯乙基)氨基]-L-苯丙氨酸,或L-苯丙氨酸氮芥,L-PAM)及其两种水解产物,单羟基美法仑(MOH)和二羟基美法仑(DOH)。反相苯基柱和由乙腈/柠檬酸盐缓冲液组成的流动相实现了等度分离和定量。已合成N,N-[双(2-羟乙基)]甲苯胺作为与DOH结构相关的内标。一种新的、准确的“动力学”校准程序使我们能够测定甚至不稳定的MOH的浓度。采用荧光检测时,L-PAM的定量下限为30 ng/ml,DOH和MOH的定量下限均为20 ng/ml。全身性和局部性美法仑治疗中的一些药代动力学数据说明了该方法的应用。